Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

NCT03988842 is registered in ClinicalTrials.gov with Victor Tapson, MD as lead sponsor.

NCT NCT03988842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03988842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Lead sponsor
Victor Tapson, MD
Phase
Phase 4
Overall status
Terminated
Start date
July 25, 2019
Completion date
April 5, 2020
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism, pulmonary embolism subacute massive, pulmonary embolism with acute cor pulmonale, pulmonary embolism with pulmonary infarction, right ventricular dysfunction, right ventricular failure